{
    "name": "prothrombin complex concentrate, human",
    "comment": "Rx",
    "other_names": [
        "Kcentra"
    ],
    "classes": [
        "Blood Components",
        "Hemostatics"
    ],
    "source": "https://reference.medscape.com/drug/kcentra-prothrombin-complex-concentrate-human-999848",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: Unknown whether distributed in human breast milk; breast feeding not advised"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Unknown whether distributed in human breast milk; breast feeding not advised"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Patients being treated with vitamin K antagonists (VKA) have underlying disease that predispose them to thromboembolic events; potential benefits of reversing VKA should be weighed against the potential risks of thromboembolic events",
                "Both fatal and nonfatal arterial and venous thromboembolic complications reported during clinical trials and postmarketing surveillance; monitor for signs and symptoms",
                "Not studied in individuals who had a thromboembolic event, MI, DIC, CVA, TIA, unstable angina, or severe PVD within the prior 3 months before administration"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Anaphylaxis or severe systemic reactions to any component",
                "Disseminated intravascular coagulation (DIC) Known heparin-induced thrombocytopenia (HIT)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Fatal and nonfatal arterial and venous thromboembolic complications reported (see Black Box Warnings)",
                "Reversing VKA therapy, due to thromboembolic complications, exposes patients to thromboembolic risk of their underlying disease; once the risk of thromboembolic events outweighs the risk of acute bleeding, resumption of anticoagulation should be carefully considered following administration of Kcentra and Vitamin K",
                "Because of risk of thromboembolism associated with reversal of VKA, closely monitor patients for signs and symptoms of thromboembolism during and after therapy administration",
                "Hypersensitivity reactions reported, including flushing, urticaria, tachycardia, anxiety, angioedema, wheezing, nausea, vomiting, hypotension, tachypnea, dyspnea, pulmonary edema, and bronchospasm",
                "Made from human blood; risk of transmitting infectious agents (eg, viruses including hepatitis and HIV, Creutzfeldt-Jakob variant or disease)"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "alteplase",
            "description": {
                "common": "alteplase, prothrombin complex concentrate, human. pharmacodynamic synergism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "anti-inhibitor coagulant complex",
            "description": {
                "common": "anti-inhibitor coagulant complex increases effects of prothrombin complex concentrate, human by pharmacodynamic synergism. Contraindicated. Coadministration increases risk of thrombosis."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "apixaban",
            "description": {
                "common": "apixaban, prothrombin complex concentrate, human. pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "argatroban",
            "description": {
                "common": "argatroban, prothrombin complex concentrate, human. pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "bivalirudin, prothrombin complex concentrate, human. pharmacodynamic synergism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dabigatran",
            "description": {
                "common": "dabigatran, prothrombin complex concentrate, human. pharmacodynamic synergism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dalteparin",
            "description": {
                "common": "dalteparin, prothrombin complex concentrate, human. pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "enoxaparin, prothrombin complex concentrate, human. pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "Factor IX",
            "description": {
                "common": "Factor IX increases effects of prothrombin complex concentrate, human by pharmacodynamic synergism. Contraindicated. Coadministration increases risk of thrombosis."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "Factor IX, recombinant",
            "description": {
                "common": "Factor IX, recombinant increases effects of prothrombin complex concentrate, human by pharmacodynamic synergism. Contraindicated. Coadministration increases risk of thrombosis."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "Factor VIIa, recombinant",
            "description": {
                "common": "Factor VIIa, recombinant increases effects of prothrombin complex concentrate, human by pharmacodynamic synergism. Contraindicated. Coadministration increases risk of thrombosis."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "heparin",
            "description": {
                "common": "heparin, prothrombin complex concentrate, human. pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "protein C concentrate",
            "description": {
                "common": "protein C concentrate increases effects of prothrombin complex concentrate, human by pharmacodynamic synergism. Contraindicated. Coadministration increases risk of thrombosis."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "reteplase",
            "description": {
                "common": "reteplase, prothrombin complex concentrate, human. pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rivaroxaban",
            "description": {
                "common": "rivaroxaban, prothrombin complex concentrate, human. pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tenecteplase",
            "description": {
                "common": "tenecteplase, prothrombin complex concentrate, human. pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tranexamic acid injection",
            "description": {
                "common": "tranexamic acid injection increases effects of prothrombin complex concentrate, human by pharmacodynamic synergism. Contraindicated. Coadministration increases risk of thrombosis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and prothrombin complex concentrate, human both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "emicizumab",
            "description": {
                "common": "prothrombin complex concentrate, human, emicizumab.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Thrombotic microangiopathy reported when aPCC was coadministered with emicizumab. Patients presented with thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury, without severe deficiencies in ADAMTS13 activity. Thromboembolism was also reported with coadministration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "Factor X, human",
            "description": {
                "common": "Factor X, human, prothrombin complex concentrate, human.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Caution is advised in patients who are receiving other plasma products that may contain Factor X, (eg, fresh frozen plasma, prothrombin complex concentrates)."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Thromboembolic events",
            "percent": "8.7"
        },
        {
            "name": "Headache",
            "percent": "7.8"
        },
        {
            "name": "Hypotension",
            "percent": "4.9"
        },
        {
            "name": "Nausea",
            "percent": "3.9"
        },
        {
            "name": "vomiting",
            "percent": "3.9"
        },
        {
            "name": "Arthralgia",
            "percent": "2.9"
        },
        {
            "name": "Hemorrhage intracranial",
            "percent": "2.9"
        },
        {
            "name": "Mental status changes",
            "percent": "2.9"
        },
        {
            "name": "Increased BP",
            "percent": "2.9"
        },
        {
            "name": "hypertension",
            "percent": "1.9"
        },
        {
            "name": "Skin laceration",
            "percent": "1.9"
        },
        {
            "name": "contusion",
            "percent": "1"
        },
        {
            "name": "hematoma",
            "percent": "1"
        },
        {
            "name": "Respiratory distress",
            "percent": "1"
        },
        {
            "name": "dyspnea",
            "percent": "1"
        },
        {
            "name": "hypoxia",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Fluid overload",
            "percent": null
        },
        {
            "name": "Breath sounds",
            "percent": null
        },
        {
            "name": "abnormal rates",
            "percent": null
        },
        {
            "name": "Chest pain",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Hypersensitivity or allergic reactions",
            "percent": null
        },
        {
            "name": "Flushing",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "tachycardia",
            "percent": null
        },
        {
            "name": "anxiety",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "wheezing",
            "percent": null
        },
        {
            "name": "nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "hypotension",
            "percent": null
        },
        {
            "name": "tachypnea",
            "percent": null
        },
        {
            "name": "dyspnea",
            "percent": null
        },
        {
            "name": "pulmonary edema",
            "percent": null
        },
        {
            "name": "and bronchospasm",
            "percent": null
        },
        {
            "name": "Thromboembolic complications",
            "percent": null
        },
        {
            "name": "Arterial thromboembolic events",
            "percent": null
        },
        {
            "name": "including acute MI and arterial thrombosis",
            "percent": null
        },
        {
            "name": "venous thromboembolic events",
            "percent": null
        },
        {
            "name": "including PE and venous thrombosis",
            "percent": null
        },
        {
            "name": "and DIC",
            "percent": null
        }
    ]
}